I-Flow Corporation (NASDAQ:IFLO) announced today that it will address institutional shareholders at the First Annual Lazard Life Sciences Conference, Tuesday afternoon, November 30, 2004 at 2:00 p.m. EST.

The Lazard conference will take place November 30th and December 1st at The Mandarin Oriental Hotel in New York, NY. Donald M. Earhart, I-Flow's Chairman, President, and Chief Executive Officer will make a presentation describing the Company's growth strategies and market opportunities for its Regional Anesthesia business.

I-Flow Corporation is an emerging leader in post-surgical pain relief. The Company's ON-Q(R) PainBuster(R) Post-Op Pain Relief System provides targeted pain relief after surgery only where the body needs it, delivering a non-narcotic, pain-numbing medication directly to an incision site for up to five days. The anesthetic is administered through a specially-designed catheter inserted by a surgeon during surgery. ON-Q PainBuster is cleared for use by the U.S. Food & Drug Administration (FDA), and is now labeled to significantly reduce pain and narcotics intake after surgery.

You can access a live webcast of the 30 minute presentation, after registration, from the Investors link or the Investors' Event Calendar link at www.IFLO.com. The webcast will be available for replay at approximately 2:40 p.m. EST at this same internet address for 90 days. Audio streams require Windows Media installations.

About I-Flow

I-Flow Corporation (www.IFLO.com) designs, develops and markets technically advanced, low cost drug delivery systems and services that are redefining the standard of care by providing life enhancing, cost effective solutions for pain relief.

Certain disclosures made by the Company in this press release and in other reports and statements released by the Company are and will be forward-looking in nature, such as comments that express the Company's opinions about trends and factors that may impact future operating results. Disclosures that use words such as the Company "believes," "anticipates," or "expects" or use similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ from those expected, and readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to republish revised forward-looking statements to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures made by the Company in this release which seek to advise interested parties of the risks and other factors that affect the Company's business, as well as in the Company's periodic reports on Forms 10-K, 10-Q, and 8-K filed with the Securities and Exchange Commission. The risks affecting the Company's business include, among others: implementation of our direct sales strategy; dependence on our suppliers and distributors; reliance on the success of the home health care industry; our continuing compliance with applicable laws and regulations, such as the Food, Drug and Cosmetic Act, and the FDA's concurrence with our management's subjective judgment on compliance issues; the reimbursement system currently in place and future changes to that system; competition in the industry; economic and political conditions in foreign countries; currency exchange rates; inadequacy of booked reserves; technological changes; and product availability and acceptance. All forward-looking statements, whether made in this release or elsewhere, should be considered in context with the various disclosures made by the Company about its business.